Should the UK continue breast screening?
This article was originally published in Clinica
Executive Summary
The value of the UK breast screening programme, heralded as a flagship for preventive medicine, is being questioned by one of its pioneers. Professor Michael Baum, research director of the Institute of Cancer Research, suggests that more lives might be saved by reallocating scarce cancer resources to drug research and other emerging treatments. Prof Baum has resigned from the government's NHS breast cancer screening advisory group to voice his concerns.